These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23546688)

  • 1. Therapeutic potential of SIGIRR in systemic lupus erythematosus.
    Wang C; Feng CC; Pan HF; Wang DG; Ye DQ
    Rheumatol Int; 2013 Aug; 33(8):1917-21. PubMed ID: 23546688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The decreased frequency of SIGIRR-positive CD4+ T cells in peripheral blood of patients with SLE and its correlation with disease activity.
    Wang DY; Su C; Chen GM; Pan HF; Wang FM; Liu GL; Hao L; Wang DG; Ye DQ
    Mol Biol Rep; 2015 Feb; 42(2):423-30. PubMed ID: 25287661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis.
    Drexler SK; Kong P; Inglis J; Williams RO; Garlanda C; Mantovani A; Yazdi AS; Brennan F; Feldmann M; Foxwell BM
    Arthritis Rheum; 2010 Aug; 62(8):2249-61. PubMed ID: 20506350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis.
    Lech M; Skuginna V; Kulkarni OP; Gong J; Wei T; Stark RW; Garlanda C; Mantovani A; Anders HJ
    J Pathol; 2010 Apr; 220(5):596-607. PubMed ID: 20112371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The largely normal response to Toll-like receptor 7 and 9 stimulation and the enhanced expression of SIGIRR by B cells in systemic lupus erythematosus.
    Zhu YY; Su Y; Li ZG; Zhang Y
    PLoS One; 2012; 7(8):e44131. PubMed ID: 22952899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens.
    Lech M; Kulkarni OP; Pfeiffer S; Savarese E; Krug A; Garlanda C; Mantovani A; Anders HJ
    J Exp Med; 2008 Aug; 205(8):1879-88. PubMed ID: 18644972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling.
    Wald D; Qin J; Zhao Z; Qian Y; Naramura M; Tian L; Towne J; Sims JE; Stark GR; Li X
    Nat Immunol; 2003 Sep; 4(9):920-7. PubMed ID: 12925853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus.
    Li J; Pan HF; Cen H; Tian J; Ma Y; Tao JH; Ye DQ
    Mol Biol Rep; 2011 Aug; 38(6):4077-81. PubMed ID: 21107711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIGIRR deficiency contributes to CD4 T cell abnormalities by facilitating the IL1/C/EBPβ/TNF-α signaling axis in rheumatoid arthritis.
    Teng X; Mou DC; Li HF; Jiao L; Wu SS; Pi JK; Wang Y; Zhu ML; Tang M; Liu Y
    Mol Med; 2022 Nov; 28(1):135. PubMed ID: 36401167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin.
    Giannoudaki E; Stefanska AM; Lawler H; Leon G; Hernandez Santana YE; Hassan N; Russell SE; Horan R; Sweeney C; Preston RS; Mantovani A; Garlanda C; Fallon PG; Walsh PT
    J Immunol; 2021 Jul; 207(2):651-660. PubMed ID: 34253575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily.
    Thomassen E; Renshaw BR; Sims JE
    Cytokine; 1999 Jun; 11(6):389-99. PubMed ID: 10346978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice.
    Costello DA; Watson MB; Cowley TR; Murphy N; Murphy Royal C; Garlanda C; Lynch MA
    J Neurosci; 2011 Mar; 31(10):3871-9. PubMed ID: 21389242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach.
    Gong J; Wei T; Stark RW; Jamitzky F; Heckl WM; Anders HJ; Lech M; Rössle SC
    J Struct Biol; 2010 Mar; 169(3):323-30. PubMed ID: 20025973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIGIRR, a negative regulator of TLR/IL-1R signalling promotes Microbiota dependent resistance to colonization by enteric bacterial pathogens.
    Sham HP; Yu EY; Gulen MF; Bhinder G; Stahl M; Chan JM; Brewster L; Morampudi V; Gibson DL; Hughes MR; McNagny KM; Li X; Vallance BA
    PLoS Pathog; 2013; 9(8):e1003539. PubMed ID: 23950714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation.
    Kadota C; Ishihara S; Aziz MM; Rumi MA; Oshima N; Mishima Y; Moriyama I; Yuki T; Amano Y; Kinoshita Y
    Clin Exp Immunol; 2010 Nov; 162(2):348-61. PubMed ID: 21077278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIGIRR participates in negative regulation of LPS response and tolerance in human bladder epithelial cells.
    Li D; Zhang X; Chen B
    BMC Immunol; 2015 Dec; 16():73. PubMed ID: 26634342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-TLR2 antibody attenuates the Aβ-mediated inflammatory response in microglia through enhanced expression of SIGIRR.
    Costello DA; Carney DG; Lynch MA
    Brain Behav Immun; 2015 May; 46():70-9. PubMed ID: 25620736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Colon Tumors Express a Dominant-Negative Form of SIGIRR That Promotes Inflammation and Colitis-Associated Colon Cancer in Mice.
    Zhao J; Bulek K; Gulen MF; Zepp JA; Karagkounis G; Martin BN; Zhou H; Yu M; Liu X; Huang E; Fox PL; Kalady MF; Markowitz SD; Li X
    Gastroenterology; 2015 Dec; 149(7):1860-1871.e8. PubMed ID: 26344057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.
    Bulek K; Swaidani S; Qin J; Lu Y; Gulen MF; Herjan T; Min B; Kastelein RA; Aronica M; Kosz-Vnenchak M; Li X
    J Immunol; 2009 Mar; 182(5):2601-9. PubMed ID: 19234154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 receptor associated kinase 1 is a potential therapeutic target of anti-inflammatory therapy for systemic lupus erythematosus.
    Li M; Yu D; Ni B; Hao F
    Mol Immunol; 2017 Jul; 87():94-101. PubMed ID: 28431280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.